Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior 		0.010 Biomarker phenotype BEFREE Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders. 19320528 2009
CUI: C0392702
Disease: Abnormal involuntary movement
Abnormal involuntary movement 		0.020 GeneticVariation disease BEFREE In the present study, we examined the relationship between the CYP2D6*10 C188T polymorphism and the TD occurrence in 216 Chinese schizophrenic patients (113 patients with TD and 103 patients without TD) and explored the correlation between the TD severity assessed by the Abnormal Involuntary Movement Scale (AIMS) and each C188T genotype in the 113 TD patients. 15118351 2004
CUI: C0392702
Disease: Abnormal involuntary movement
Abnormal involuntary movement 		0.020 GeneticVariation disease BEFREE In patients tested for CYP2D6, an association between genotype and tardive dyskinesia (including Abnormal Involuntary Movement Scale scores) was found. 20031087 2010
CUI: C4021768
Disease: Abnormality of metabolism/homeostasis
Abnormality of metabolism/homeostasis 		0.100 Biomarker phenotype HPO
CUI: C0001175
Disease: Acquired Immunodeficiency Syndrome
Acquired Immunodeficiency Syndrome 		0.010 Biomarker group BEFREE Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome. 10952478 2000
CUI: C0234376
Disease: Action Tremor
Action Tremor 		0.300 Biomarker phenotype CTD_human Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. 15570195 2004
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.010 GeneticVariation disease BEFREE This study aims to investigate the different clinically relevant allele variants (allele frequencies) of CYP2D6 gene and to determine whether a specific genotype of CYP2D6 gene (based on genetic polymorphism "allelic types" and combination) have impact on metoprolol effectiveness (clinical outcome) in patients who have acute coronary syndrome (ACS). 30965129 2019
CUI: C0546126
Disease: Acute Confusional Senile Dementia
Acute Confusional Senile Dementia 		0.300 Biomarker disease CTD_human The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease. 7574463 1995
CUI: C0948089
Disease: Acute Coronary Syndrome
Acute Coronary Syndrome 		0.010 GeneticVariation disease BEFREE Correlation of CYP2D6 allelic polymorphism to outcome of acute coronary syndrome in mid-Euphrates Iraqi patients on metoprolol therapy. 30965129 2019
CUI: C1735368
Disease: Acute dystonia
Acute dystonia 		0.010 Biomarker phenotype BEFREE We theorize that CYP2D6 governs the risk of metoclopramide-related acute dystonia through its role in the synthesis of serotonin, which inhibits the dopamine tone. 31507424 2019
CUI: C0162565
Disease: Acute intermittent porphyria
Acute intermittent porphyria 		0.010 GeneticVariation disease BEFREE High penetrance of acute intermittent porphyria in a Spanish founder mutation population and CYP2D6 genotype as a susceptibility factor. 30808393 2019
CUI: C2609414
Disease: Acute kidney injury
Acute kidney injury 		0.300 Biomarker disease CTD_human Acute kidney injury in patients with inactive cytochrome P450 polymorphisms. 19814645 2009
CUI: C1565662
Disease: Acute Kidney Insufficiency
Acute Kidney Insufficiency 		0.300 Biomarker disease CTD_human Acute kidney injury in patients with inactive cytochrome P450 polymorphisms. 19814645 2009
CUI: C0085669
Disease: Acute leukemia
Acute leukemia 		0.050 Biomarker disease BEFREE A significant increased risk was found for CYP2D6 poor metabolizer phenotype and acute leukaemia [odds ratio (OR) = 1.69, 95% confidence interval (CI) 1.17-2.43], a risk also found in AML and ALL.No interaction was found with smoking. 11037802 2000
CUI: C0085669
Disease: Acute leukemia
Acute leukemia 		0.050 GeneticVariation disease BEFREE CYP2D6*3 or *4 polymorphism might not be associated with AL susceptibility. 24112176 2013
CUI: C0085669
Disease: Acute leukemia
Acute leukemia 		0.050 GeneticVariation disease BEFREE Maternal Exposure to Pesticides, Paternal Occupation in the Army/Police Force, and CYP2D6*4 Polymorphism in the Etiology of Childhood Acute Leukemia. 29432309 2018
CUI: C0085669
Disease: Acute leukemia
Acute leukemia 		0.050 GeneticVariation disease BEFREE This case-control study suggests a contribution of CYP2D6 and GSTM1 null variants in the development of acute leukaemia. 17581325 2007
CUI: C0085669
Disease: Acute leukemia
Acute leukemia 		0.050 Biomarker disease BEFREE Role of CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias. 16493615 2006
CUI: C0023449
Disease: Acute lymphocytic leukemia
Acute lymphocytic leukemia 		0.050 Biomarker disease BEFREE The genetic polymorphisms of biotransformation phase I enzymes, cytochrome P450 (CYP1A1 and CYP2D6), and phase II enzymes, glutathione S-transferase (GSTM1 and GSTT1), were analyzed in 204 healthy persons and 348 leukemia patients, who suffered from also acute lymphoblastic leukemia (ALL), acute nonlymphoblastic leukemia (ANLL) chronic myelogenous leukemia (CML), from the Han ethnic group in Changsha City of Hunan Province of China. 18414197 2008
CUI: C0023449
Disease: Acute lymphocytic leukemia
Acute lymphocytic leukemia 		0.050 GeneticVariation disease BEFREE Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children. 15382273 2004
CUI: C0023449
Disease: Acute lymphocytic leukemia
Acute lymphocytic leukemia 		0.050 Biomarker disease BEFREE Role of the CYP2D6, EPHX1, MPO, and NQO1 genes in the susceptibility to acute lymphoblastic leukemia in Brazilian children. 19593802 2010
CUI: C0023449
Disease: Acute lymphocytic leukemia
Acute lymphocytic leukemia 		0.050 GeneticVariation disease BEFREE The NAT2 slow-acetylator, CYP1A1*2A and GSTM1 null genotypes were shown to be significant risk determinants of ALL (OR=1.6, 1.8 and 1.8, respectively), whereas, polymorphisms in CYP2D6 and GSTT1 genes did not seem to play an important role in the aetiology of ALL. 10953966 2000
CUI: C0023449
Disease: Acute lymphocytic leukemia
Acute lymphocytic leukemia 		0.050 Biomarker disease BEFREE A significant increased risk was found for CYP2D6 poor metabolizer phenotype and acute leukaemia [odds ratio (OR) = 1.69, 95% confidence interval (CI) 1.17-2.43], a risk also found in AML and ALL.No interaction was found with smoking. 11037802 2000
CUI: C0023465
Disease: Acute monocytic leukemia
Acute monocytic leukemia 		0.010 GeneticVariation disease BEFREE CYP2D6*1/*3 genotype frequency also showed a protective association in AML patients (OR = 0.09, 95% CI = 0.01-1.7; P = 0.04). 16493615 2006
CUI: C0155626
Disease: Acute myocardial infarction
Acute myocardial infarction 		0.010 AlteredExpression disease BEFREE Higher CYP2D6 activity seems to be associated with VRDs complicating AMI, being a negative prognostic factor for patients' survival. 18648788 2008